2-166251789-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_001365536.1(SCN9A):c.3448G>A(p.Glu1150Lys) variant causes a missense change. The variant allele was found at a frequency of 0.000117 in 1,612,486 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_001365536.1 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SCN9A | NM_001365536.1 | c.3448G>A | p.Glu1150Lys | missense_variant | Exon 18 of 27 | ENST00000642356.2 | NP_001352465.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SCN9A | ENST00000642356.2 | c.3448G>A | p.Glu1150Lys | missense_variant | Exon 18 of 27 | NM_001365536.1 | ENSP00000495601.1 | |||
SCN9A | ENST00000303354.11 | c.3448G>A | p.Glu1150Lys | missense_variant | Exon 18 of 27 | 5 | ENSP00000304748.7 | |||
SCN9A | ENST00000409672.5 | c.3415G>A | p.Glu1139Lys | missense_variant | Exon 18 of 27 | 5 | ENSP00000386306.1 | |||
SCN9A | ENST00000645907.1 | c.3415G>A | p.Glu1139Lys | missense_variant | Exon 18 of 27 | ENSP00000495983.1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152028Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000282 AC: 7AN: 248222Hom.: 0 AF XY: 0.0000149 AC XY: 2AN XY: 134642
GnomAD4 exome AF: 0.000127 AC: 186AN: 1460458Hom.: 0 Cov.: 31 AF XY: 0.000134 AC XY: 97AN XY: 726500
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152028Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74256
ClinVar
Submissions by phenotype
not provided Uncertain:2
Published functional studies demonstrate that the variant does not alter the function of the Nav1.7 channel (Le Cann et al., 2021); Previously reported in a patient with severe myalgia, pain in extremities, childhood onset hypotonia, visual impairments, intestinal paralysis, and 3-methylglutaconic and 3-methylglutaric aciduria; the authors were unable to establish pathogenicity of the variant (Le Cann et al., 2021).; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 33487118, 27535533) -
BS3 -
Inborn genetic diseases Uncertain:1
The p.E1139K variant (also known as c.3415G>A), located in coding exon 17 of the SCN9A gene, results from a G to A substitution at nucleotide position 3415. The glutamic acid at codon 1139 is replaced by lysine, an amino acid with similar properties. This alteration has been reported in a female with myalgia and fibromyalgia. The same group also performed whole cell patch clamp studies which did not show a change compared to the wild type (Le Cann K et al. Channels (Austin), 2021 12;15:208-228). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Generalized epilepsy with febrile seizures plus, type 7;C2752089:Neuropathy, hereditary sensory and autonomic, type 2A Uncertain:1
This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 1139 of the SCN9A protein (p.Glu1139Lys). This variant is present in population databases (rs367794835, gnomAD 0.005%). This missense change has been observed in individual(s) with clinical features of genetic epilepsy with febrile seizures plus (internal data). ClinVar contains an entry for this variant (Variation ID: 471112). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt SCN9A protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Primary erythromelalgia;C1833661:Paroxysmal extreme pain disorder;C1855739:Channelopathy-associated congenital insensitivity to pain, autosomal recessive;C2752089:Neuropathy, hereditary sensory and autonomic, type 2A Other:1
Variant interpreted as Uncertain significance and reported on 08-23-2018 by Lab or GTR ID 26957. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at